Overview#

Stifel has adjusted its price target for Beta Bionics, Inc. (NASDAQ:BBNX) from $22.00 to $20.00, while still keeping a Buy rating on the stock. Currently, the stock trades at $12.27, which is below this new target. Analysis suggests that the stock may be overvalued based on Fair Value metrics.

Financial Performance#

In its first-quarter 2026 results, Beta Bionics reported a solid performance with a 58% increase in revenue over the past year, totaling $110.24 million. The company's gross margin, which indicates the percentage of revenue that exceeds the cost of goods sold, reached 59.5%, surpassing Stifel's estimate of 54.3%. This strong margin is close to the company’s gross profit margin of 57% over the last twelve months.

Guidance and Estimates#

Management has raised its guidance for 2026 in terms of revenue, gross margin, and the percentage of new patients starting treatment through Pharmacy. However, Stifel has lowered its estimates for EBITDA, which stands for Earnings Before Interest, Taxes, Depreciation, and Amortization, due to increasing operating expenses.

Recent Challenges#

The company faced challenges with new patient starts in the fourth quarter of 2025, which negatively impacted its stock performance. However, new patient starts in the first quarter of 2026 showed a smaller decline than expected, falling between 10% to 20% quarter-over-quarter, compared to Stifel’s estimate of a 20% drop. Additionally, Beta Bionics holds more cash than debt, providing it with financial flexibility during this growth phase.

Earnings Report#

Beta Bionics recently reported a 57% year-over-year revenue increase, reaching $27.6 million in the first quarter of 2026. Despite this growth, the company missed its earnings per share (EPS) expectations, posting an EPS of -0.49 against a forecast of -0.33, resulting in a significant negative surprise. Wolfe Research also adjusted its price target for Beta Bionics to $17.00 from $20.00, while maintaining an Outperform rating. The revenue growth was largely driven by a 22% increase in durable medical equipment and a notable 180% rise in pharmacy sales, with a revenue split of approximately 60% from durable medical equipment and 40% from pharmacy sales.